About Schwarz Pharmain Monheim , headquartered SCHWARZ PHARMA () is a listed company with about 400 employees worldwide. The company develops novel drugs in the therapeutic areas of the central nervous system. Expects to markets innovative drugs for the treatment of cardiovascular and gastrointestinal disorders to treat. In 2005 the SCHWARZ PHARMA Group has achieved global sales of almost 1 billion, the company has a strong international presence with subsidiaries in Europe, USA and Asia. For inquires please contact Antje Witte .

About otelixizumabotelixizumab, an experimental humanized anti-CD3 monoclonal antibody, a T-cell immunotherapy for the treatment of type 1 diabetes is developed and other autoimmune diseases. Otelixizumab targets CD3, involving a T lymphocyte receptor in normal cell signaling.Agency for International Development and in partnership with government from Haiti. The increase in will help to incomes for small farmers and promote sustainability of Haitian agriculture.. Forthcoming Organic EventsBIO Investor Forum October 28-29, 2009 San Francisco What, CAAdvanced Business Development Course the 30th October 2009 Vienna, AustriaBIO Europe International Partnering Conference November 2-4, 2009 Vienna, AustriaPacific Rim Summit on Industrial Biotechnology and Bioenergy eighth December – 11, 2009 Honolulu,are available. Increase agriculture productivity by supporting U.S. Government – out Haitian farmers experience dramatic increases in crops this year thanks to an innovative program out of the U.S.

Haitian agricultural output processing and marketing been stagnation or decline since 50 years of. $ 126 thousand Haitians have employed in agriculture but still to 23 % imported of Haiti be food.